|
||||||||||||
|
|
![]() |
|
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
|
|||
|
|
||||||||||||
![]() |
|
Ventac Partners and NTNU, Department of Biology, and NTNU Technology
Transfer AS have designed a five-day course that takes participants
through the entire entrepreneurship process from early scientific discovery
to commercialization. The course is open to participants from Norway
as well as international participants.
Life Science follow up project: Capturing the Delta Oppurtunity In 2004, Ventac Partners (VP) and HKSTP published a study concluding that Hong Kong could build a robust biotech industry. The present report reaffirms that conclusion and documents the continued strong capabilities of the region in the life sciences. Click the picture to the left to read more and here to see the full report in pdf format.
APIM Therapeutics is anew spin-off from the Norwegian University of Science and Technology with potential to increase efficacy of and reduce side effects associated with a large group of existing first line chemotherapeutics. Click the picture to the left to read more.
Ventac Partners and the Academic Medical Center (AMC)of the University of Amsterdam secured 250,000 Euros in pre-seed funding from the Netherlands Genomics Initiative. Click the picture to the left to read more. |
||||||||||
![]() |
||||||||||||
![]() |
||||||||||||